PubMed HealthSearch

Biomedical subjects

F J Service

Publications and source records attributed to F J Service.

At least 19 recordsLinked to original sources

C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma.

To assess the effects of gender, age, and body mass index (BMI) on suppression of plasma C-peptide during insulin-induced hypoglycemia, 101 lean and obese, healthy men and women ages 20 to 80 yr underwent infusion of human regular insulin, 0.125 U/kg over 60 min after an overnight fast. Plasma glucose, insulin, and C-peptide were measured every 30 min for 120 min. C-peptide concentrations were influenced by gender at 30 min, by BMI at baseline and both BMI and age at all subsequent time points. Because of variations in baseline plasma C-peptide concentrations, percent decrease in C-peptide was evaluated. Significantly less percent decrease of C-peptide with increased age at 30, 60, and 90 min and with increased BMI at 30 and 60 min were noted with no effect of gender. From stepwise regression analysis using multiple, additional variables only the plasma glucose concentration at 30 min made a significant, albeit small (8%), contribution to the variability in percent decrease in C-peptide at 60 min. When C-peptide responses from eight histologically confirmed insulinoma patients were contrasted to values adjusted for age, gender, and BMI of normal subjects, all insulinoma patients had abnormal responses when percent decrease in C-peptide was used, whereas only four insulinoma patients had abnormal response when actual C-peptide concentrations were used.

Adult

Occult functioning insulinomas: which localizing studies are indicated?

BACKGROUND: An occult insulinoma refers to a biochemically proven tumor with an anatomic site that remains indeterminate before operation. The amount of radiologic localization for such patients is debatable. METHODS: Sixty-five patients with sporadic insulinomas were surgically treated at the Mayo Clinic between January 1980 and December 1990. True occult tumors were present in 31% of these patients (n = 20). Thirty-eight negative preoperative localization studies were performed, with 10 patients undergoing more than one study. A benign adenoma was found in 19 patients when they underwent exploratory operation, whereas one patient had malignant disease with hepatic metastases. Thirteen patients underwent intraoperative ultrasonography with a 7.5 MHz real-time high-resolution transducer. RESULTS: Solitary lesions were successfully removed either by enucleation or by distal pancreatectomy in all 19 patients with benign disease. CONCLUSIONS: This high success rate in the management of occult insulinomas suggests that extensive preoperative radiologic investigation is neither indicated nor cost-effective.

Adolescent

Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.

For the 60-year period from 1927 through 1986, we assessed the incidence, recurrence, and long-term survival among all Mayo Clinic patients with histologically confirmed functioning insulinoma. With use of the complete medical record system at Mayo and the comprehensive epidemiologic data base of residents of Olmsted County, Minnesota, we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma. The median age (and range) of these patients at surgical diagnosis was 47 (8 to 82) years, and 59% were female patients. During the study period, eight cases of insulinoma occurred among residents of Olmsted County; their age and gender distributions were similar to those of the total cohort. The incidence of insulinoma among residents of Olmsted County increased during the study period to a stable level during the last 2 decades of 4 cases per 1 million person-years. For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma. The risk of recurrence was greater among patients with MEN I (21% at 10 and 20 years) than in those without MEN I (5% at 10 years and 7% at 20 years). Although survival of the total cohort was not significantly impaired, it was significantly worse than expected for patients with malignant insulinoma (29% versus 88% expected at 10 years postoperatively). We conclude that insulinoma is less rare than previously suspected. After successful surgical removal, the long-term risk of recurrent insulinoma is relatively high in patients with MEN I; for patients with benign disease, the long-term survival is normal.

Adolescent

Hypoglycemias.

Low plasma glucose concentrations that may or may not be sufficiently low to result in symptoms can be observed as a concomitant of several diverse diseases. Treatment of the primary underlying disorder usually alleviates the hypoglycemia. For patients whose primary symptom is that of hypoglycemia, it is essential to confirm that the plasma glucose concentration is low during the occurrence of symptoms. Symptoms that occur after meals usually are mild and rarely signify serious disease. With rare exceptions, hypoglycemia resulting in major symptoms occurs in the food-deprived state. Lower concentrations of plasma insulin and C-peptide and a concomitant low plasma glucose are major clues to a correct diagnosis.

Blood Glucose

Pancreas transplantation at Mayo: III. Multidisciplinary management.

Although pancreas transplantation is a complicated procedure, a good level of success has been achieved because of the introduction of cyclosporine for immunosuppression, improved methods for diagnosing rejection, and a multidisciplinary approach to management. Our immunosuppressive regimen was quadruple therapy with induction by using Minnesota antilymphoblastic globulin. A biopsy technique was instituted in which the pancreas specimens were obtained under cystoscopic direction during episodes of hypoamylasuria. The criteria for rejection episodes were not only biochemical abnormalities but also histologic confirmation and a follow-up to exclude other causes of graft dysfunction. Infectious disease management included use of oral selective bowel decontamination for 3 weeks after transplantation. At the Mayo Clinic between October 1987 and December 1988, 16 patients received pancreaticoduodenal allografts (both kidney and pancreas in 13 and pancreas only in 3 after a prior successful kidney transplantation). In two pancreas and one kidney allograft, function was lost. One patient died of multiorgan failure. The cystoscopically directed biopsy technique was performed 23 times with minimal complications and a 93% success rate. The metabolic results have been excellent; the glycosylated hemoglobulin level was normal 3 to 6 months after transplantation. The quality of life was significantly improved in almost all patients. Nutritional assessment revealed little deterioration after transplantation. With a multidisciplinary approach, the needed answers about the effect of pancreas transplantation on the degenerative complications of diabetes should be forthcoming.

Adult

Lack of effect of gastric inhibitory polypeptide on hepatic and extrahepatic insulin action.

To assess the influence of enteric factors on insulin action, seven lean healthy subjects were studied under conditions of hyperinsulinemic euglycemic glucose clamp, double isotope administration, and enteral vs. parenteral glucose infusion. In random order, glucose and mannitol radiolabeled with [2-3H]glucose were infused intraduodenally for 4 h while the systemic rate of glucose turnover was assessed by [6-14C]glucose. During the final hour of the study, plasma glucose, insulin, C-peptide, glucagon, cholecystokinin, and neurotensin were similar under both experimental conditions. Despite an increase in gastric inhibitory polypeptide concentration during combined enteral and iv glucose infusion to levels that mimicked meal ingestion, total glucose infusion rate, insulin-induced stimulation of glucose uptake, and insulin-induced suppression of hepatic glucose release were comparable to those observed during iv glucose administration. These data indicate that under conditions of modest hyperinsulinemia and euglycemia, gastric inhibitory polypeptide did not influence hepatic or extrahepatic insulin action.

Adult

Meal-related insulin requirements.

Postprandial glycemia correlates with meal size in insulin dependent diabetic and nondiabetic persons. Decline in meal tolerance as the day progresses noted in nondiabetics does not occur in IDDM. Meal size correlates with insulin secretion in nondiabetics and amounts of insulin infused by an artificial endocrine pancreas to IDDM. There is no diurnal change in insulin secretion in nondiabetics or insulin infusion into IDDM but not amounts of insulin secretions by nondiabetics. Sequence of meal ingestion influenced amounts of insulin infused into IDDM. It is unclear to what extent variation in carbohydrate contribution or composition affect postprandial events. More precise quantitative measures of meal-related glucose behavior such as mean indices of meal excursions may be useful. CSII used in IDDM has been shown to normalize postprandial endogenous glucose production.

Blood Glucose

Diagnostic interpretation of the intravenous tolbutamide test for insulinoma.

The plasma glucose and insulin responses to intravenous administration of tolbutamide in patients with insulinoma and healthy control subjects were compared to determine the sensitivity and specificity of the intravenous tolbutamide test for the diagnosis of insulinoma. The records of 406 healthy persons without concurrent disease known to affect glucose homeostasis or insulin concentrations and 41 patients with histologically confirmed insulinoma who underwent standard intravenous tolbutamide testing during the period from 1976 to 1986 were reviewed. The 5th percentile of the mean of plasma glucose levels at the 120-, 150-, and 180-minute points (G120-180) after injection of tolbutamide was 55 mg/dl for lean and 62 mg/dl for obese control subjects. With 95% specificity, the sensitivity of these criteria was 95% for lean and 100% for obese patients with insulinoma. Minimal differences were observed between men and women. At 95% specificity, the sensitivities were less for the ratio of the 180-minute plasma glucose to fasting plasma glucose level (64% in lean and 75% in obese patients), for mean of plasma insulin at the 120-, 150-, and 180-minute points (IRI120-180) (53% in lean and 36% in obese patients), for maximal insulin concentration (27% in lean and 31% in obese patients), for increase in insulin concentration above basal (18% in lean and 23% in obese patients), and for the combined criteria of the 5th percentile of G120-180 and the 95th percentile of IRI120-180 (47% in lean and 73% in obese patients).(ABSTRACT TRUNCATED AT 250 WORDS)

Adenoma, Islet Cell

Management of noninsulin-dependent diabetes mellitus.

Management of the patient with NIDDM requires the skill and patience of the physician and the input of a health team, including the dietitian and nurse educator. With perseverance and careful follow up, most treatment goals can be achieved in these patients. The attitude of neglect and easy treatment goals that previously characterized the care of these patients are not justified.

Continuity of Patient Care

Hypoglycemia.

Hypoglycemia is an abnormally low plasma glucose concentration and not a disease entity. With the exception of the effect of hypoglycemic drugs (insulins and sulfonylureas), hypoglycemia arises from an aberration in one or more mechanisms involved in glucose homeostasis. Progress in our knowledge of glucose homeostasis in the past decade and the development of radioimmunoassay for insulin, the primary hypoglycemic hormone, and C-peptide, a marker of insulin secretion, have facilitated both the understanding and diagnostic precision of hypoglycemic disorders.

Humans

Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization.

Twenty-nine patients with surgically proved benign pancreatic insulinoma were studied by preoperative or intraoperative sonography. Twenty-five patients had solitary pancreatic tumors; four had multiple tumors. Six of the patients with solitary insulinomas and one of the patients with multiple insulinomas had undergone previous unsuccessful exploration. Preoperative sonography was performed in 24 patients with solitary insulinomas, and 15 (63%) were localized. Intraoperative sonography was performed in 22 patients with solitary insulinomas, and 19 (86%) were visualized without having been previously located by palpation. Four of these visible solitary tumors (18%) were not detected by palpation at surgery. All the solitary insulinomas were detected with the combination of palpation and intraoperative sonography. In each of the six patients with solitary insulinoma who had undergone previous surgery, the tumor was visible with intraoperative sonography, which also demonstrated nonpalpable insulinomas in two of the four patients with multiple tumors. Preoperative real-time sonography is a sensitive, noninvasive, inexpensive method for localization of insulinoma. Intraoperative high-frequency sonography is a highly sensitive method for the detection of insulinoma. Intraoperative sonography is also valuable to determine the relationship of the insulinoma to pancreatic and bile ducts and thereby facilitate safe enucleation.

Adenoma, Islet Cell

The surgical aspects of insulinomas.

The clinical diagnosis of insulinoma rests on the demonstration of Whipple's triad (symptoms of hypoglycimia, low circulating glucose and prompt relief of symptoms after glucose administration). Biochemically, the association of an increased value of immunoreactive insulin with a low glucose value is diagnostic of insulin-mediated hypoglycemia. Angiographic localization of these tumors is accomplished in more than 90% of cases. The pathologic changes are usually due to a single adenoma, for which surgical enucleation is the procedure of choice. Malignancy and persistent hypoglycemia occur in slightly less than 10% of cases and can be fairly successfully managed by diazoxide and streptozotocin.

Adenoma, Islet Cell